FibroGen to Present at Upcoming Investor Conferences
November 06 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique
Conterno, Chief Executive Officer, will participate in fireside
chats at the following healthcare conferences:
- Stifel 2020 Virtual Healthcare
Conference on Tuesday, November 17, 2020 at 1:20 PM Eastern
Time
- Jefferies Virtual London Healthcare
Conference on Thursday, November 19, 2020 at 12:35 PM Eastern
Time
A live audio webcast will be available on the “Events &
Presentations” section of the FibroGen Investor webpage at
https://fibrogen.gcs-web.com/. A replay will be available for
approximately 30 days.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to
discovering, developing and commercializing a pipeline of
first-in-class therapeutics. The company applies its pioneering
expertise in hypoxia-inducible factor (HIF) and connective tissue
growth factor (CTGF) biology to advance innovative medicines to
treat unmet needs. The Company is currently developing and
commercializing roxadustat, an oral small molecule inhibitor of HIF
prolyl hydroxylase activity, for anemia associated with chronic
kidney disease (CKD). Roxadustat is also in clinical development
for anemia associated with myelodysplastic syndromes (MDS) and for
chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), locally advanced
unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy
(DMD), and coronavirus (COVID-19). For more information, please
visit www.fibrogen.com.
Contact:FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor Relations1.415.630.0131mtung@fibrogen.com
Media:Jennifer Harrington
+1.610.574.9196Jennifer.Harrington@gcihealth.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024